### **Company Overview** Tarsons Products Limited (TPL) is a leading Indian manufacturer of laboratory products, operating as one of the few Indian companies with a significant global footprint in the life sciences sector. With over **40+ years of industry presence**, Tarsons specializes in the **design, development, manufacturing, and marketing** of high-precision labware, including **consumables, reusables, and benchtop equipment**. The company serves key stakeholders such as **research institutions, academic organizations, pharmaceutical firms, biotech companies, CROs, diagnostic labs, and hospitals**, both domestically and internationally. Tarsons is recognized as one of the **top three labware manufacturers in India**, known for its **quality, reliability, and innovation**, underpinned by strong brand equity and vertical integration. --- ### **Core Business Segments** - **Product Portfolio**: Over **2,000 SKUs across 350 product segments**. - **Consumables (55%)**: Pipette tips, centrifuge tubes, cryo vials, PCR consumables, cell culture products. - **Reusables (40%)**: Bottles, carboys, beakers, measuring cylinders, racks. - **Benchtop Equipment (5%)**: Centrifuges, vortex shakers, pipettors. - **Key Brands**: Maxipense, Spinwin, Cryochill — all well-recognized by the scientific community. - **Material Standards**: Use of **medical-grade, DMF-registered resins** with minimal additives ensures low leachability and high purity, critical for life science applications. --- ### **Manufacturing & Operations** - **Six Vertically Integrated Facilities** in West Bengal across **Jangalpur, Dhulagarh, Panchla, Amta, and Burroshibtolla (I & II)**. - **Revenue Contribution (FY25)**: - Jangalpur: **59.1%** - Dhulagarh: **26.7%** - Burroshibtolla II: **6.3%**, Burroshibtolla I: **5.1%**, Kasba: **2.8%** - **Highly Automated Production**: - Robotics and human-touch-free manufacturing developed with overseas partners. - Production in **ISO Class 8 (ISO 1-14-6485 certified)**, third-party-validated cleanrooms under aseptic conditions. - **ISO and CE certified**, with sterile products undergoing **gamma irradiation (ISO 11137)**. - **In-House R&D**: Supported by a dedicated engineering team focused on precision design and liquid handling solutions. --- ### **Growth Initiatives (FY25–FY26)** #### **1. New Manufacturing & Infrastructure Projects** - **Panchla Facility (5-acre site)**: - Phase 1 commissioned in Q1 FY25; producing **bioprocess products (PETG, roller bottles)**. - Focused on **cell culture and bio-processing**, aiming to nearly double the company’s addressable market. - Expected to generate **₹400 crore annual revenue at full scale**; full ramp-up targeted by H2 FY26. - **Amta Facility (6-acre site)**: - ₹150 crore investment in a **modern fulfillment center, centralized warehouse, and in-house sterilization facility**. - Includes **gamma radiation plant (via MoU with BRIT)** to reduce dependency on external sterilization vendors. - Will enhance supply chain resilience, improve logistics turnaround, and support **scale-driven operating leverage**. - **Strategic Shift**: From capacity creation to **value generation and automation-driven efficiency**. #### **2. Backward Integration & Sterilization** - **In-house sterilization capability** is being deployed to: - Reduce current sterilization costs (~1.5% of revenue). - Improve supply security and scalability. - Increase the proportion of **sterile products in the revenue mix** (target: 50% from 25%). - Enhance captive control over critical manufacturing processes. #### **3. New Product Expansion** - **Recently Launched**: - Bioprocess products: **PET, PETG, roller bottles**. - Expansion into **PCR consumables** (since 2019), with pandemic-era scaling. - **Near-Term Launches**: - **Cell culture products** in Q4 FY25–Q1 FY26, including media bottles, flasks. - **R&D Focus**: Targeting **import-substitution segments** like robotic-handled consumables, bioprocess solutions. --- ### **Market Strategy & Global Expansion** #### **Domestic Market** - **Pan-India Distribution Network**: Supported by ~144 long-standing distributors and a dedicated sales force. - **Strategic Focus**: - **Increase wallet share** in a highly fragmented market with intense competition. - **Leverage ‘Make in India’** to capture higher domestic market share. - Overcome pricing pressures from international players subcontracting locally. - **Indian TAM Opportunity**: - **Cell culture market**: ~**₹400 crore**; Tarsons aims to capture **25–30%**. - Overall labware market shows healthy growth, especially in research and diagnostics. #### **International Market** - **Exports to 40+ Countries**, accounting for **32% of standalone revenue in FY25**. - **Dual Strategy**: - **Branded Sales**: In **emerging markets** (Asia-Pacific, Middle East, South America). - **ODM (Original Design Manufacturing)**: In **developed markets** (North America, Europe). - Supplies to **Toei Kaisha** and other global brand owners. - **Export Revenue (FY25)**: ₹99.82 crore (+20.3% YoY), supported by ODM and branded growth. #### **Acquisition of Nerbe (Germany)** - **Acquired in Jan 2024** via **Tarsons Life Science Pte. Ltd. (Singapore subsidiary)**. - Includes **Nerbe R&D GmbH and Nerbe Plus GmbH & Co. KG**, revenue ~€4.2 million (H1 FY25), down from peak pandemic levels (~€30 million). - **Strategic Benefits**: - Direct access to European markets (Germany, France, UK). - Distribution platform to cross-sell Tarsons-manufactured products in Europe. - Foundation for **future tenders and pan-European expansion**. - Integration ongoing; not yet supply-integrated into Indian facilities but planned post-Panchla stabilization. #### **Long-Term Export Vision** - Target: **Expand footprint to ~120 countries over the next 5–10 years**. - Focus: Strengthen brand presence and scale in Europe and North America despite **tariff risks (e.g., proposed 25–50% U.S. duty)**. --- ### **Competitive Positioning** - **Differentiators**: - Full vertical integration with **in-house design, mold-making, and automation**. - **Precision manufacturing** meeting international standards (ISO, CE). - **One-stop labware provider** with broad portfolio. - **Market Challenges**: - Intense domestic competition, new entrants, pricing pressures. - Global competition from MNCs leveraging local subcontractors for cost parity. - **Opportunities**: - Growing demand in **cell culture and bioprocessing**, projected to grow at **~18% CAGR** in India. - **Global shift away from Chinese manufacturing** due to tariffs and ESG norms — India well-positioned as an alternative.